Repare Therapeutics Sells RP-3467 Program to Gilead
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Repare Therapeutics ( (RPTX) ) has issued an update.
On December 23, 2025, Repare Therapeutics entered into an asset purchase agreement under which Gilead Sciences acquired all assets related to RP-3467, its Polθ ATPase inhibitor program for advanced solid tumors, for up to $30 million in cash, including $22–25 million in near-term payments and a further $5 million contingent on completion of technology transfer, while assuming specified related liabilities but leaving Repare’s other programs and core assets untouched. The transaction, announced publicly on December 24, 2025, follows New York University’s consent to assign its RP-3467 license to Gilead in exchange for a one-time $250,000 payment and represents Repare’s third and largest portfolio deal of 2025, significantly boosting its cash balance ahead of a previously announced acquisition by XenoTherapeutics and raising the company’s estimate of the cash consideration payable to shareholders at closing of that arrangement to about US$2.20 per share.
The most recent analyst rating on (RPTX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.
Spark’s Take on RPTX Stock
According to Spark, TipRanks’ AI Analyst, RPTX is a Neutral.
Repare Therapeutics’ overall stock score is driven by positive technical indicators and promising corporate developments, despite financial challenges and poor valuation metrics. The company’s strong cash position and recent trial data provide a foundation for potential future improvements.
To see Spark’s full report on RPTX stock, click here.
More about Repare Therapeutics
Repare Therapeutics is a clinical-stage precision oncology company focused on discovering and developing targeted cancer therapies using a synthetic lethality approach aimed at genomic instability and DNA damage repair, with programs including the polymerase theta (Polθ) ATPase inhibitor RP-3467 currently in early-stage clinical trials for advanced solid tumors.
Average Trading Volume: 846,705
Technical Sentiment Signal: Hold
Current Market Cap: $110.8M
For a thorough assessment of RPTX stock, go to TipRanks’ Stock Analysis page.
